Stocks Health care DRUG
NASDAQ · Health careBright Minds Biosciences Inc. (DRUG)
It posted a net loss of CA$2.8M. At September 30, 2024 it held CA$5.7M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on December 23, 2025.
Key facts about Bright Minds Biosciences Inc.
- Net worth
- Bright Minds Biosciences Inc. has a market value (market cap) of $223.6M at the latest share price, and shareholders' equity of CA$5.5M on its balance sheet at September 30, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2024 operations used CA$1.9M of cash.
- Latest report
- The latest periodic report (annual report (Canadian issuer), 40-F) was filed with the SEC on December 23, 2025 and covers the period to September 30, 2025. Open on SEC EDGAR
What Bright Minds Biosciences Inc. does
Bright Minds Biosciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DRUG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | n/a | -CA$2.8M | -CA$0.65 | n/a |
| 2023 | n/a | -CA$7.4M | -CA$1.98 | n/a |
| 2022 | n/a | -CA$15M | -CA$6.06 | n/a |
| 2021 | n/a | -CA$8.7M | -CA$4.82 | n/a |
| 2021 | n/a | -CA$480.4K | -CA$0.65 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Bright Minds Biosciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- October 2, 2026
- October 1, 2026
- August 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- June 3, 2026
- June 2, 2026
Insider trades
What the people running Bright Minds Biosciences Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 28, 2026 | Cormorant Asset Management, LPFormer 10% Owner | Soldindirect | 109,331 | $9.8M |
Who owns DRUG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ian McDonald13D, may seek influence | 13.7% | July 2, 2026 |
| Janus Henderson Group PLC13G, passive | 13.1% | May 15, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 9.17% | August 14, 2026 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 5.2% | May 12, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 5% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 100 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 1,349,107 | new |
| Cormorant Asset Management, LP | 900,000 | -159,331 |
| BlackRock, Inc. | 686,184 | +64,251 |
| Vivo Capital, LLC | 557,172 | 0 |
| Vestal Point Capital, LP | 545,000 | +52,681 |
| Braidwell LP | 483,822 | -55,886 |
| Driehaus Capital Management LLC | 433,377 | +862 |
| Balyasny Asset Management L.P. | 345,053 | +47,895 |
| Adage Capital Partners GP, L.L.C. | 335,000 | -160,743 |
| Point72 Asset Management, L.P. | 327,416 | new |
| Deerfield Management Company, L.P. | 283,000 | 0 |
| RA Capital Management, L.P. | 265,000 | 0 |
| Parkman Healthcare Partners LLC | 205,053 | +164,955 |
| Mpm Bioimpact LLC | 202,114 | -10,061 |
| Wellington Management Group Llp | 171,315 | +34,638 |
| Goldman Sachs Group Inc | 133,689 | +59,320 |
| Eventide Asset Management, LLC | 130,013 | 0 |
| State Street Corp | 122,178 | +13,939 |
| Seven Grand Managers, LLC | 120,000 | 0 |
| Great Point Partners LLC | 109,603 | -110,397 |
Insiders
1 insiders reported holding 950,000 shares in total, about $21.5M at the last price.
| Holder | Shares |
|---|---|
| Cormorant Asset Management, LPFormer 10% Owner | 950,000950,000 held indirectly |
Questions about DRUG
What does Bright Minds Biosciences Inc. do?
Bright Minds Biosciences Inc. is a company in the Health care sector, listed on NASDAQ as DRUG. Its shares trade on NASDAQ under the ticker DRUG.
What is Bright Minds Biosciences Inc.'s net worth?
Bright Minds Biosciences Inc. has a market value (market cap) of $223.6M at the latest share price, and shareholders' equity of CA$5.5M on its balance sheet at September 30, 2024. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bright Minds Biosciences Inc. profitable?
No. In fiscal 2024 it reported a net loss of CA$2.8M.
When did Bright Minds Biosciences Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on December 23, 2025. It covers the period to September 30, 2025. Its newest filing of any kind is the foreign issuer update from November 2, 2026.
Similar companies
Compare DRUG with
Follow DRUG
Get an email when Bright Minds Biosciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bright Minds Biosciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.